LDS/Medical Tests/Amyloid Protein Identification

Amyloid Protein Identification

Amyloidosis is a heterogeneous group of clinical conditions characterized by systemic or localized tissue deposition of stable filamentous proteins aggregates. The proteins are characteristically arranged in a β-pleated sheet configuration, that are resistant to proteolysis and therefore accumulate over time. Except in cases associated with plasma cell dyscrasias, the type of amyloid protein present in tissue deposits cannot be readily diagnosed by measuring plasma proteins. Typically, the diagnosis of amyloidosis requires biopsy of affected organs or unaffected tissues such as abdominal fat pad, salivary gland or rectal mucosa. Microscopically amyloid appears as amorphous deposits of pink, hyaline material on H&E stained sections. Confirmation can be done by demonstrating typical apple-green birefringence of the material when stained with Congo red and visualized with polarized light.

Amyloidosis can be either acquired or hereditary. Most of the acquired amyloidosis occurs as a result of an underlying plasma cell dyscrasia, chronic inflammation, or aging. At least 26 different proteins have been identified as primary components of amyloid. Some of the common proteins involved in systemic amyloidosis include immunoglobulin light and heavy chains (AL and AH amyloid), serum amyloid A (AA amyloid), prealbumin (transthyretin) (ATTR amyloid), and β2-microglobulin (Aβ2 amyloid). In localized amyloidosis, the major proteins involved include amyloid β-protein (Aβ), amylin (IAPP amyloid), and cystatin C (ACys amyloid). In addition to these proteins, amyloid deposits can also contain glycosaminoglycans, apolipoprotein E, and serum amyloid P component.

The treatment of amyloidosis depends on the specific sites of amyloid deposition and the protein involved. Therefore, it is important to accurately identify the specific amyloid protein that is involved in the pathogenesis of the disease. This can be achieved using immunohistochemistry, amino acid sequencing or mass spectrometry.

  • Aids in the subtyping of amyloidosis
  • Useful in definitive identification of specific type of amyloid protein deposits

Based on the type of protein deposited in specific tissues

Positive (detected in):

  • Plasma cell dyscrasias (AL amyloid)
  • Chronic infectious or inflammatory processed (AA amyloid)
  • Dialysis-related amyloidosis (beta-2-microglobulin)
  • Hereditary amyloidosis (Transthyretin, Cystatin C, others)
  • Senile systemic amyloidosis

Organ specific amyloidosis:

  • Alzheimers
  • Hepatic
  • Skin

Negative (not detected)

Liquid Chromatography Tandem Mass Spectrometry, Histopathological stains (Congo red stain).

Histopathological slides, Fixed tissue slides, Frozen tissue, Cytological smears, Nonparaffin embedded tissue.

Stability

Ambient (Preferable).

Serum amyloid A (SAA), immunoglobulin light chain, β2-microglobulin, amyloid β-protein (Aβ), amylin, cystatin C, Apolipoprotein E.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Annu Rev Med. 2006;57:223-41. [PMID: 16409147]
  • Scand J Clin Lab Invest. 2009;69:18-21. [PMID: 19199126]
  • Arch Neurol. 2011;68:195-9. [PMID: 20937937]
  • Blood. 2009;114:4957-9. [PMID: 19797517]
  • Hortin GL. Amino acids, Peptides, and Proteins. Textbook of Clinical Chemistry and Molecular Diagnostics. 5th ed. 2012. Page 509 – 63.
  • Johnson AM. Amino acids, peptides, and proteins. Tietz textbook of clinical chemistry and Molecular Diagnostics, 4th ed. 2006. Page 531-95.